Lassa virus and Ebola virus are two of the mostdevastatinghumanpathogensandinfectionwithbothcan lead to severe hemorrhagic fever with case fatality rates in excess of 70%. It is estimated that tens of thousandsofpeoplediefromLassafevereachyear.DespitethehighcasefatalityratesofhospitalizedEbola and Lassa fever patients, it is wellestablishedthatasymptomaticormildlysymptomaticinfectionsoccurin both Lassa fever and Ebola. We know that virus genetics play key roles in determining disease severity, however, mechanistic insights are lacking and no systematic studies have been performed toidentifyvirus correlates ofhumandisease.Similarly,ahighproportionofLassafeverandEbolasurvivorsdevelopserious long-termsymptomsassociatedwiththeirdisease,butvirusfactorsthatmaydeterminethesecomplications remain elusive. The central hypothesis of this project, is that speci?c genetic factors in Lassa and Ebola viruses critically in?uence infection outcomes. Working directly with unique Lassa and Ebolapatientandsurvivorcohortsin WestAfrica,wewillidentifyLassavirusandEbolavirusfactorsthataredeterminantsofhumandisease.We will integrate high-throughput ?omics? approaches, high-containment experimentation, and computational modelingtoelucidatemolecularnetworksthatdetermineinfectiousdiseaseseverity.Basedonthese?ndings, wewillbuildpredictivemodelsthatcanbeusedtodetermineriskfromLassavirusandEbolavirusinfection. We will achieve these goals by completing three overarching goals. In Speci?c Aim 1, we will create and analyzelarge-scalegenomicdatasetsofLassaandEbolaviruses,andgenotypeofinfectedpatients.Wewill performdeepinvestigationsofhowthevirusesevolveastheytransmitfromtheirnaturalreservoirstohumans and between humans, and determine how that can a?ect clinical outcomes. In Speci?c Aim 2, we will functionally characterize, in a high-throughput manner, individual Lassa virus and Ebola virus mutations hypothesizedtoin?uenceinfectiousoutcomes.Finally,inSpeci?cAim3wewillperformexperimentsinhigh containment to determine functional e?ects of individual mutations in Lassa virus and Ebola virus, and investigatemechanismsofimmuneescapeandinfection.Aspartofthisaim,wewillalsoengineerantibodies to better target both viruses, which can be used as a starting point for future therapeutics.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Program--Cooperative Agreements (U19)
Project #
Application #
Study Section
Special Emphasis Panel (ZAI1)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Scripps Research Institute
La Jolla
United States
Zip Code
Siddle, Katherine J; Eromon, Philomena; Barnes, Kayla G et al. (2018) Genomic Analysis of Lassa Virus during an Increase in Cases in Nigeria in 2018. N Engl J Med 379:1745-1753
Saphire, Erica Ollmann; Schendel, Sharon L; Fusco, Marnie L et al. (2018) Systematic Analysis of Monoclonal Antibodies against Ebola Virus GP Defines Features that Contribute to Protection. Cell 174:938-952.e13
Holmes, Edward C; Rambaut, Andrew; Andersen, Kristian G (2018) Pandemics: spend on surveillance, not prediction. Nature 558:180-182
Suchard, Marc A; Lemey, Philippe; Baele, Guy et al. (2018) Bayesian phylogenetic and phylodynamic data integration using BEAST 1.10. Virus Evol 4:vey016
Gunn, Bronwyn M; Yu, Wen-Han; Karim, Marcus M et al. (2018) A Role for Fc Function in Therapeutic Monoclonal Antibody-Mediated Protection against Ebola Virus. Cell Host Microbe 24:221-233.e5
Saphire, Erica Ollmann; Schendel, Sharon L; Gunn, Bronwyn M et al. (2018) Antibody-mediated protection against Ebola virus. Nat Immunol 19:1169-1178
Rambaut, Andrew; Drummond, Alexei J; Xie, Dong et al. (2018) Posterior Summarization in Bayesian Phylogenetics Using Tracer 1.7. Syst Biol 67:901-904